Methods In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
PMC Ipamorelin raised GH without elevating cortisol or ACTHkey for preserving muscle while avoiding stress-hormone spikes
Ulie, 2025)
Nests of epidermal melanocytes are absent in purely intradermal nevi
A groundbreaking study by Mayo Clinic has revealed that genetic testing can predict which patients are most likely to experience nausea when taking GLP-1 agonist medications such as Wegovy and Zepbound
Carbohydrates (e.g., glucose) and lipids (e.g., free fatty acids or FFAs) are the most important sources of energy for most organisms, including humans